Minicircle
Minicircle develops a human genetic enhancement platform to facilitate life extension capabilities. Its platform uses expressive DNA mini circles to add genes to the human body without altering its pre-existing genome that lets healthcare practitioners to relieve suffering and enrich the condition through means of developing and delivering safe, accessible gene therapy. The company was founded in 2019 and is headquartered in Los Angeles, California.
Industries
Nr. of Employees
small (1-50)
Products
Reversible Gene Therapy Platform
A gene therapy platform using highly expressive DNA plasmids to add genes to the human body without altering the pre-existing genome, designed to be non-inflammatory and non-heritable.
HIV Gene Therapy
A plasmid therapy delivering human-derived broadly neutralizing antibodies to neutralize HIV particles in blood serum, designed for high-temperature climates and aims to eradicate HIV.
Follistatin Gene Therapy
A gene therapy trial for enhancing quality of life, increasing bone density and muscle mass, reducing body fat, improving insulin sensitivity, and reducing the epigenetic rate of aging.
MINI-001
A follistatin-based therapy candidate in Phase I clinical development, targeting multiple therapeutic modalities.
MINI-002
An HIV plasmid therapy in Phase I clinical development, designed for high-temperature climates and aims to be a functional cure and prophylactic for HIV.
MINI-003
A testosterone-based therapy candidate in discovery and preclinical development, addressing low testosterone levels.
Reversible Gene Therapy Platform
A gene therapy platform using highly expressive DNA plasmids to add genes to the human body without altering the pre-existing genome, designed to be non-inflammatory and non-heritable.
HIV Gene Therapy
A plasmid therapy delivering human-derived broadly neutralizing antibodies to neutralize HIV particles in blood serum, designed for high-temperature climates and aims to eradicate HIV.
Follistatin Gene Therapy
A gene therapy trial for enhancing quality of life, increasing bone density and muscle mass, reducing body fat, improving insulin sensitivity, and reducing the epigenetic rate of aging.
MINI-001
A follistatin-based therapy candidate in Phase I clinical development, targeting multiple therapeutic modalities.
MINI-002
An HIV plasmid therapy in Phase I clinical development, designed for high-temperature climates and aims to be a functional cure and prophylactic for HIV.
MINI-003
A testosterone-based therapy candidate in discovery and preclinical development, addressing low testosterone levels.